Data protection Impressum

Biotech

AC Immune will receive a USD 4 million research grant from The Vijay and Marie Goradia Charitable Foundation to extend Part 1 of the Phase 2 VacSYn trial of ACI-7104, its immunotherapy for early Parkinson's disease.

AC Immune secures USD 4 million grant to advance its Parkinson’s immunotherapy

6 July 2026

Top Stories Western Switzerland

Top Stories from Western Switzerland (June 2026)

29 June 2026

At a recent BioAlps INSIDE event in Fribourg, the Biofactory Competence Center showcased how its bioprocess expertise helps partners across Western Switzerland move from research to production, with collaborations spanning Lausanne start-up Regenosca and the CHUV.

Fribourg’s Biofactory Competence Center turns biotech research into scalable production

23 June 2026

Neuchâtel’ CSEM contributed system integration and bonding expertise to the development of Hamilton's GlucoSense, a sensor that delivers continuous glucose monitoring inside bioreactors used in biologics production.

CSEM helps bring real-time glucose monitoring to bioreactor manufacturing

3 June 2026

A new EY study ranks Switzerland 3rd worldwide for corporate R&D intensity and 6th for total spending, with 14 Swiss companies among the global top 500.

Switzerland ranks 3rd globally for corporate R&D intensity

18 May 2026

The Swiss Biotech Report 2026 reveals record sector revenues and a landmark year for private funding, as talent and international collaboration continue to underpin Switzerland's position at the forefront of global life sciences.

Swiss Biotech Report 2026: talent and tenacity drive record performance

5 May 2026

Top Stories Western Switzerland

Top Stories from Western Switzerland (April 2026)

29 April 2026

Lausanne-based AC Immune has amended its license and collaboration agreement with Eli Lilly to advance new Tau Morphomer small molecule candidates for Alzheimer's disease and other neurodegenerative diseases, with IND-enabling studies set to commence in the first half of 2026.

AC Immune secures CHF 10 million from Lilly to advance Alzheimer’s therapy

15 April 2026

Four life sciences projects were recognized at BIND – BioInnovation Day 2026, held at CHUV Lausanne on 1 April 2026, as the region's flagship academic innovation showcase drew 340 participants from academia, healthcare, industry, and investment.

BIND 2026 highlights Western Switzerland’s life sciences innovation pipeline

14 April 2026

Global in vitro diagnostics leader bioMérieux has invested over CHF 1 million in Geneva-based scale-up Plair, whose RAPID-C+ system is setting a new standard for real-time viable particle monitoring in pharmaceutical cleanrooms.

bioMérieux invests in Plair to advance environmental monitoring in pharma

30 March 2026

1 2 3 4 5 … 18